Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Sep;89(3):330–335. doi: 10.1111/j.1365-2249.1992.tb06957.x

Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.

L E Rönnblom 1, E T Janson 1, A Perers 1, K E Oberg 1, G V Alm 1
PMCID: PMC1554468  PMID: 1516252

Abstract

Patients with malignant midgut carcinoid tumours received recombinant interferon-alpha 2a (rIFN-alpha 2a) or rIFN-alpha 2a and chemotherapy (streptozocin and doxorubicin) for 6 months, and then rIFN-alpha 2a alone. Antibodies, mainly of IgG type, binding to rIFN-alpha 2a developed in nine of 22 patients (41%), as determined by immunoassay. In seven patients, antibodies also neutralized the biologic (anti-viral) activity of rIFN-alpha 2a. Anti-IFN-alpha 2a antibodies were equally frequent in both sexes and treatment groups, but were not observed in those patients (n = 8) that had previously received other types of IFN. Antibodies appeared after a median of 6 months of rIFN-alpha 2a treatment and had a median duration of 6 months. The anti-IFN-alpha 2a antibody titres declined with time with no obvious relation to change of therapy, also during continued IFN-alpha 2a treatment. High titres of neutralizing antibodies appeared to impair anti-tumoural effects in individual potential responders. Anti-IFN-alpha 2a antibodies further examined in six patients bound to native IFN-alpha subtypes present in both allogenic and autologous leucocyte IFN-alpha. Such autoantibodies neutralized the biologic activity of autologous IFN-alpha in two patients, and in a third were partially neutralizing.

Full text

PDF
330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis. 1991 Apr;163(4):882–885. doi: 10.1093/infdis/163.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Autoimmune thyroid disease in interferon-treated patients. Lancet. 1985 Jul 13;2(8446):100–101. [PubMed] [Google Scholar]
  3. Cantell K., Hirvonen S. Large-scale production of human leukocyte interferon containing 10(8) units per ml. J Gen Virol. 1978 Jun;39(3):541–543. doi: 10.1099/0022-1317-39-3-541. [DOI] [PubMed] [Google Scholar]
  4. Conlon K. C., Urba W. J., Smith J. W., 2nd, Steis R. G., Longo D. L., Clark J. W. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990 May 15;65(10):2237–2242. doi: 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  5. Freund M., von Wussow P., Diedrich H., Eisert R., Link H., Wilke H., Buchholz F., LeBlanc S., Fonatsch C., Deicher H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol. 1989 Jul;72(3):350–356. doi: 10.1111/j.1365-2141.1989.tb07715.x. [DOI] [PubMed] [Google Scholar]
  6. Gobl A. E., Funa K., Alm G. V. Different induction patterns of mRNA for IFN-alpha and -beta in human mononuclear leukocytes after in vitro stimulation with herpes simplex virus-infected fibroblasts and Sendai virus. J Immunol. 1988 May 15;140(10):3605–3609. [PubMed] [Google Scholar]
  7. Grandér D., Oberg K., Lundqvist M. L., Janson E. T., Eriksson B., Einhorn S. Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 1990 Aug 11;336(8711):337–340. doi: 10.1016/0140-6736(90)91879-f. [DOI] [PubMed] [Google Scholar]
  8. Ikeda Y., Miyake K., Toda G., Yamada H., Yamanaka M., Oka H. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease. J Gastroenterol Hepatol. 1989 Sep-Oct;4(5):411–418. doi: 10.1111/j.1440-1746.1989.tb01738.x. [DOI] [PubMed] [Google Scholar]
  9. Itri L. M., Campion M., Dennin R. A., Palleroni A. V., Gutterman J. U., Groopman J. E., Trown P. W. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer. 1987 Feb 1;59(3 Suppl):668–674. doi: 10.1002/1097-0142(19870201)59:3+<668::aid-cncr2820591317>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  10. Moertel C. G., Rubin J., Kvols L. K. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989 Jul;7(7):865–868. doi: 10.1200/JCO.1989.7.7.865. [DOI] [PubMed] [Google Scholar]
  11. Oberg K., Alm G., Magnusson A., Lundqvist G., Theodorsson E., Wide L., Wilander E. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst. 1989 Apr 5;81(7):531–535. doi: 10.1093/jnci/81.7.531. [DOI] [PubMed] [Google Scholar]
  12. Oberg K., Funa K., Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983 Jul 21;309(3):129–133. doi: 10.1056/NEJM198307213090301. [DOI] [PubMed] [Google Scholar]
  13. Oberg K., Norheim I., Lind E., Alm G., Lundqvist G., Wide L., Jonsdottir B., Magnusson A., Wilander E. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep. 1986 Nov;70(11):1297–1304. [PubMed] [Google Scholar]
  14. Pierangeli S. S., Sonnenfeld G. Effects of interferon-gamma and tumor necrosis factor-alpha on macrophage enzyme levels. J Interferon Res. 1989 Feb;9(1):1–9. doi: 10.1089/jir.1989.9.1. [DOI] [PubMed] [Google Scholar]
  15. Porres J. C., Carreño V., Ruíz M., Marrón J. A., Bartolomé J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol. 1989 May;8(3):351–357. doi: 10.1016/0168-8278(89)90034-2. [DOI] [PubMed] [Google Scholar]
  16. Prümmer O., Frickhofen N., Digel W., Heimpel H., Porzsolt F. Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol. 1991 Feb-Mar;62(2-3):76–80. doi: 10.1007/BF01714905. [DOI] [PubMed] [Google Scholar]
  17. Rönnblom L. E., Alm G. V., Oberg K. E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991 Aug 1;115(3):178–183. doi: 10.7326/0003-4819-115-3-178. [DOI] [PubMed] [Google Scholar]
  18. Rönnblom L. E., Alm G. V., Oberg K. E. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990 Mar;227(3):207–210. doi: 10.1111/j.1365-2796.1990.tb00144.x. [DOI] [PubMed] [Google Scholar]
  19. Wahlund K. G., Edlén B. Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column. Clin Chim Acta. 1981 Feb 19;110(1):71–76. doi: 10.1016/0009-8981(81)90302-8. [DOI] [PubMed] [Google Scholar]
  20. von Wussow P., Freund M., Block B., Diedrich H., Poliwoda H., Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet. 1987 Sep 12;2(8559):635–636. doi: 10.1016/s0140-6736(87)93034-0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES